Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Rises By 56.3%

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,668,357 shares, an increase of 56.3% from the August 15th total of 1,067,589 shares. Currently, 4.5% of the shares of the stock are sold short. Based on an average trading volume of 35,561,049 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HOWL. Weiss Ratings raised shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Wall Street Zen raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $4.00.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock traded up $0.04 during midday trading on Thursday, reaching $0.96. 571,048 shares of the company’s stock traded hands, compared to its average volume of 2,793,299. The company has a market cap of $46.80 million, a price-to-earnings ratio of -1.27 and a beta of 0.51. The company’s 50 day simple moving average is $0.61 and its 200 day simple moving average is $0.62. Werewolf Therapeutics has a 52 week low of $0.27 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.36. The company had revenue of $21.00 million for the quarter, compared to the consensus estimate of $21.00 million. As a group, equities research analysts predict that Werewolf Therapeutics will post -0.89 earnings per share for the current year.

Insider Transactions at Werewolf Therapeutics

In other news, Director Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total value of $33,302.99. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 23.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new stake in Werewolf Therapeutics during the 2nd quarter worth about $37,000. Bank of America Corp DE bought a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at about $112,000. Finally, BlackRock Inc. bought a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at about $37,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company uses its proprietary INDUKINE platform to design conditionally activated cytokines, which are intended to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues.

Werewolf’s pipeline has included WTX-124, an investigational interleukin-2 therapy designed to promote the expansion and activation of immune cells in tumors, and WTX-330, an investigational interleukin-12 therapy intended to activate both innate and adaptive immune responses.